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BUT 
Le but de ce sujet de recherche est d'évaluer le taux de succès et les complications à long 
terme de la sclérectomie profonde non pénétrante avec implant de collagène (SPIC) chez les 
patients atteints de glaucome à angle ouve1i. 
METODES ET PATIENTS 
Il s'agit d'une étude clinique, prospective, monocentrique, non-randomisée, effectuée sur 105 
patients atteints d'un glaucome à angle ouve1i médicalement non-contrôlé. Ces patients ont 
tous bénéficiés d'une SPIC, effectuée selon le geste chirurgicale standard (technique décrite 
dans l'article). Dans le cadre de cette étude, nous avons effectué un bilan ophtalmologique 
complet avant l'acte chirurgical puis un suivi postopératoire à 1et7 jours; l,2,3,6,9,12 mois 
et ensuite tous les 6 mois durant les dix années suivantes. 
RESULTATS 
Le suivit moyen de cette étude s'étend sur 101.5 ± 43 .1, [3-144] mois ( moyenne ± écart type, 
[étendue]). La pression intraoculaire (PIO) préopératoire était élevée à 26.8 ± 7.7, [14-52] 
mmHg, et l'acuité visuelle corrigée à 0.71±0.33, [0.02-1.5]. Au terme des dix années après le 
traitement chirurgical, le nombre de patients suivit était de 52 avec une pression intraoculaire 
abaissée à 12.2 ± 4.7, [6-20] mmHg et une acuité visuelle corrigée de 0.63 ± 0.34, [0.01-1.2]. 
Le nombre de médicaments par patient a diminué de 2.3 ± 0.7, [1-4] à 1.3 ± 1.1, [0-3]. 
Dix ans après la SPIC, une pression intraoculaire ::; 21 mmHg sans médicaments (succès 
complet) était obtenue chez 47.7 % des patients et 89 % avec ou sans traitement 
médicamenteux (succès relatif). Les gestes postopératoires additionnels par gonioponcture ont 
été effectués sur 61 yeux (59.8%) et les injections sous-conjonctival de 5-fluorouracil ont été 
pratiquées sur 25 yeux dont 5 incluant un needling. 
CONCLUSIONS 
Le suivit à long terme sur une période de dix ans, démontre que la sclérectomie profonde avec 
implant de collagène (SPIC) est efficace dans le contrôle de la pression intraoculaire et 
présente peu de complications postopératoires. 
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Abstract 
Purpose: 
To evaluate the long term success rate and complications of non penetrating deep 
sclerectomy with collagen implant (DSCI) in open-angle glaucoma. 
Patients and Methods: 
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Clinical, prospective, monocentric, non-randomized, unmasked study on 105 patients 
with medically uncontrolled glaucoma. A standard procedure DSCI was performed. Complete 
examinations were performed before surgery and postoperatively at 1 and 7 days; 1, 2, 3, 6, 9, 
12 months and then every 6 months during the 10 following years. 
Results: 
The mean follow-up was 101.5 ± 43.1, [3-144) months (mean ± SD, [range]). The 
preoperative intraocular pressure (IOP) was 26.8 ± 7.7, [14-52) mmHg and the best corrected 
visual acuity (BCV A) O. 71 ± 0.33, [0.02-1.5). Ten years after surgery IOP was 12.2 ± 4. 7, [ 6-
20) mmHg and BCVA 0.63 ± 0.34, [0.01-1.2) (number ofremaining patients= 52). The mean 
number of medications per patient went from 2.3 ± 0.7, [ 1-4) down to 1.3 ± 1.1, [0-3). An IOP 
:::; 21 mmHg without medication was achieved in 47.7 % patients and in 89% with or without 
treatment. One major complication was reported. Goniopuncture was performed in 61 eyes 
(59.8%), 5-fluorouracil treatment given to 25 patients postoperatively and included needling 
(n=5). 
Conclusions: 
Based on a 10 year follow-up deep sclerectomy with collagen implant demonstrated its 
efficacy in controlling IOP with few postoperative complications. 
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Introduction 
Deep sclerectomy with collagen implant (DSCI) is a non-penetrating filtration 
procedure used for the surgical treatment ofmedically uncontrolled open-angle glaucoma. It 
was first described by Fyodorov et al in 1989. 1 It was conceived in an attempt to lower the 
incidence of early postoperative complications of conventional trabeculectomy (such as 
hypotony, hyphema, flat anterior chamber, choroidal detachment, choroidal effusion or 
hemorrhage, surgery-induced cataract and endophthalmitis) 2-8, without compromising on the 
success rate ofintraocular pressure (IOP) reduction.9-11 
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Medium term studies of this surgi cal procedure have already been reported in our 
previous reports. 12-14' 25 In this study we present the long-tenn results (10 years) of DSCI. The 
IOP control, the rate of complications and the reduction of glaucoma treatment for the initial 
102 patients were studied. 
Patients and Methods 
Case selection 
This clinical, prospective, monocentric, non-randomized, unmasked study was 
performed on 105 eyes of 105 patients with open-angle glaucoma. All operations were 
performed by the same surgeon (A.M). Surgeries were performed between June 1994 and 
January 1997. These were the initial patients who underwent DSCI for this diagnosis at the 
Jules Gonin Eyes Hospital in Lausanne, Switzerland. 
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Inclusion criteria were: medically uncontrolled primary open-angle, pseudoexfoliative, 
pseudophakic, normal tension, pigmentary, aphakic, traumatic and open angle uveitic 
glaucomas (table 1). Medically uncontrolled glaucoma was defined as an IOP higher than 21 
mmHg under a maximal tolerable glaucoma therapy with evidence of progression ofvisual 
fields defects and or optic nerve cupping. Previous ocular surgery such as filtering or cataract 
extraction was nota criterion for excluding patients from this study. Exclusion criteria were: 
angle-closure, neovascular, congenital or juvenile glaucomas, lmown allergy to porcine 
collagen, previous argon laser trabeculectomy or eye surgery within 6 months prior to 
enrollment in the study, unwillingness to participate in the study, and pregnant or breast 
feeding women. Patients with operative perforation of the trabeculo-Descemet's membrane 
were purposely removed from this study. 
The study was approved by the Ethics Committee of the University of Lausanne. 
Every patient gave written informed consent before surgery. None of the authors have any 
financial interest in the study. 
Preoperative examination 
The data were obtained from the medical records of the patients. Every patient 
underwent complete ophthalmic examination that included best corrected visual acuity 
(BCVA) measured at 6 meters on Snellen's chart, biomicrosopy, Goldmann applanation 
tonometer IOP measurements, anterior chamber angle assessment using a 4 mÜTors contact 
lens, and fundus examination. The visual fields were tested using the Octopus 123 program 
G 1 (Interzeag AG, Schlieren, Switzerland). 
Postoperative follow-up 
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Postoperative evaluation which included all preoperative examinations except for the 
visual fields were perfonned at 1 and 7 days; 1, 2, 3, 6, 9, 12 months and thcn every 6 months 
thereafter to complete a 10 years follow-up. The visual field examination was repeated every 
year. Complications are defined on table 3. Mains outcomes were the IOP, the BCVA, the 
number of medications, and the nature and rates of complication. 
Surgical technique 
All surgeries were performed under retrobulbar anesthesia. The technique has been 
described in details elsewhere. 12 Briefly a superficial scleral flap was created. A deep scleral 
flap dissected down to the Schlemm's canal and a trabeculo-Descemet's membrane was 
performed. The inner wall of Schlemm's canal was peeled off and a collagen implant sutured 
in the deep scleral bed. The superficial scleral flap was repositioned over the implant and 
secured with 2 untight sutures (Figure 1 A-F). 
Postoperatively patients were treated with topical 6000 U/ml polymyxin, 0.35 % 
neomycin and 0.1 % dexamethasone tid for 4 weeks and with topical fluorometholone 1 
mg/ml tid for 3 months thereafter. 
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Glaucoma collagen implant 
The collagen implant is a cylindrical device (length: 2.5 mm; diameter: 1 mm) made 
from lyophilized porcine scleral collagen 12 (Aquaflow ® Staar Surgical AG, Nidau, 
Switzerland). This bio-compatible material is not known to induce systemic immunologie 
reactions. 15 Acting as a space maintainer after hydration the implant is progressively degraded 
roughly 6 to 9 months after surgery. 16• 17 
Additional procedures 
The additional procedures are reported on table 2 and were indicated based on the 
clinical aspect of the filtering bleb. Laser goniopuncture (Microruptor II; Lasag AG, Thun, 
Switzerland) in Q-switch mode (5 to 8 mJ) creates microscopie holes in the trabeculo-
Descemet's membrane allowing a direct passage of aqueous humor from the anterior chamber 
to the intra-scleral space. This procedure transforms a non-penetrating filtration procedure 
into a penetrating one. 18' 19 After laser treatment, topical prednisolon acetate 1 % was 
administered tid for three days. Glaucoma medications was reintroduced when IOP > 18 
mmHg. 
Success rate 
Surgety was considered as a complete success when IOP was :S 21 mmHg without 
glaucoma medication at last follow-up, as a qualified success when IOP was :S 21 mmHg 
including medication. lt was defined as a failure when IOP was < 6 mmHg or> 21 mmHg 
despite glaucoma medication, the eye required further glaucoma drainage surgery, developed 
phtisis bulbi, or lost light perception. 
Statistical analysis 
Results were analyzed using the Student's t test for comparison ofmeans, chi-square 
analysis for 2 x 2 tables, and Kaplan-Meier survival curves for long term success rate 
analysis. P was considered significant when <0.05. 
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Results 
One hundred and five eyes from 105 patients were enrolled in the study. The mean age 
of the patients at the time of surge1y was 68.0 years ± 12.6, [ 43-102] (mean ± SD, [range]), 
and 21 patients (20%) had previous ocular surgeries. The mean follow-up was 101.5 ± 43.1, 
[3-144] months and the me di an was 120 months. During the study 29 patients <lied, while 24 
were lost of follow-up. Preoperative diagnoses are presented on table 1. 
Mean preoperative IOP was 26.8 ± 7.7, [14-52] mmHg, mean postoperative IOP at 1 
day was 5.1 ± 3.3, [0-15] mmHg (reduction from preoperative value of 80.9 %), at 3 months 
12.3 ± 3.7, [5-27] mmHg (-54.1 %), at 3 years 13.3 ± 3.7, [6-24] mmHg (-50.4 %), at 5 years 
12.5 ± 3.6, [6-21] mmHg (-53.4 %), at 8 years 11.9 ± 3.9, [4-21] mmHg (-55.6 %) and at 10 
years 12.2 ± 4.7, [6-20] mmHg (-54.5 %). Figure 2 shows a steep reduction in IOP on the first 
postoperative day that gradually stabilized through the first month at around 12 mmHg. The 
mean IOP remained at that level for the next l 0 years, with concurrent medication when 
necessary. 
The mean number of medications per patient went from a preoperative value of 2.3 ± 
0.7, [1-4] down to 1.3 ± 1.1, [0-3] at last follow-up, representing a reduction of43.5 %. This 
reduction was more pronounced shortly after surge1y but showed slow and graduai increase 
overtime (Figure 3). At 120 months and without antiglaucoma medication 47.7% of patients 
had an IOP <21 mm Hg and 43.2% achieved an IOP < 15 mmHg. With medication, 88.9% 
and 85.6% of the patients achieved the same targets, respectively. 
Based on cumulative survival curve the success rate at 10 years was 44.6 % and 77 .6 
% for complete and qualified success, respectively (Figure 4). One patient was defined as a 
failure due to IOP > 21 mmHg (mean IOP 22.5 mmHg) that was stabilized with medication. 
Eighteen patients had failed procedure and required further glaucoma drainage surge1y. This 
second deep sclerectomy was performed on average 60 .4 months [ 1 month-10 years] after the 
initial DSCI. These patients were then all well controlled after the second procedure (IOP at 
10 years: 12.6 ± 3.7, [8-15] mmHg). 
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The BCVA decreased on the first postoperative day from 0.71±0.33, [0.02-1.5] 
(preoperatively) to 0.53 ± 0.28, [0.02-1.25]. It retumed just below preoperative level during 
the first month after surgery and remained stable for the following 10 years (Figure 5). When 
lens opacities induced a drop in BCV A, cataract extraction was proposed and performed 
during the follow-up (n=42). 
Preoperatively mean defect and corrected lost variance were 13.1 ± 7.4, [0.2-29] [dB] 
and 45.0 ± 35.0, [1.4-149] [dB2], respectively, and went to 9.1±6.8, [0.1-18] [dB] and 36.8 ± 
27.9, [0.5-110] [dB2], respectively, 10 years later. 
There was only one significant complication during surge1y that consisted in a 
malignant glaucoma due to ciliary bloc. This complication was treated with cycloplegia 
medication, the IOP at the end of the follow-up period was 11 mmHg. Table 3 shows the 
postoperative complications. Minor complications such as transient (< 5 days) hypotony, 
limited filtering bleb leakage, and subtle choroidal detachment were not comparable in 
respect to severity with the long-term trabeculectomy-related complications such as 
prolonged shallow or flat anterior chamber, surgery-induced cataract, or bleb-related 
endophthalmitis. 
Twenty-five patients (24.5 %) required subconjunctival 5-FU injections to treat bleb 
fibrosis or encapsulation. The mean number of injections per patients was 2.9 ± 1.9, [1-7] and 
the mean time between DSCI and injection was 1.8 ± 2.6, [0.25-12] months. From these 25 
patients, 5 ( 4.9 %) had additional procedures, such as needling (n=5), to treat encysted blebs. 
No needling alone was perfonned without 5-FU injection. 
Goniopuncture with the Nd: Y AG laser was performed in 61 patients (59.8 %). The 
mean number of goniopunctures per patient was 1.1 ± 0 .4, [ 1-3]. Delay between DSCI and 
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goniopuncture was ranging from 1 to 119 months, with the median at 29 months. The mean 
IOP before goniopuncture was 19.8 ± 5.5, [14-46] mmHg. The IOP decreased to 12 ± 6.4, [5-
20] mmHg 15 minutes after laser treatment, thus representing a 39.4 % IOP reduction. 
For the assessment of success, patients undergoing either 5-FU and/or needling and/or 
Nd: Y AG goniopuncture were considered a failure only if the IOP after such additional 
procedures was not lowered < 21 mmHg. 
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Discussion 
Trabeculectomy is a penetrating filtration surgery widely used for the surgical 
treatment of medically uncontrolled glaucoma. The penetrating nature of this procedure leads 
to several postoperative complications such as hypotony, hyphema, flat anterior chamber, 
choroïdal detachment, choroïdal effusion or hemorrhage, endophthalmitis and surgery-
induced cataract. Even with a modified trabeculectomy 20 the predictability of the first day 
IOP is variable and additional procedures may have to be performed (e.g. laser suture lyses, 
injection of viscoelastics in the anterior chamber, needling, releasable sutures). In an attempt 
to lower the incidence of such complications, non-penetrating filtration surgery was 
developed. 1' 21 DSCI allows a progressive filtration of aqueous through the thin remaining 
trabeculo-Descemet's membrane into the intrascleral reservoir. In their ultrasound 
biomicroscopy study, Chiou et al 16' 17 speculated that aqueous, shunted into this intrascleral 
room, was filtered to the subconjunctival and scleral space, then eventually through the thin 
remaining scleral wall and into the suprachoroidal space, which offers 2 new aqueous outflow 
mechanisms compared to trabeculectomy. To enhance filtration and to prevent the collapse of 
the intrascleral space Koslov et al 21 proposed the use of a collagen implant placed within the 
scleral bed. Similarly, Sanchez et al 22 and Shaarawy et al 26• 27 confirmed that the surgical 
outcome was better when the deep sclerectomy was performed with the insertion of a collagen 
implant. 
The major advantage of DSCI over standard trabeculectomy is the non-perforation of 
the anterior chamber, allowing a progressive decrease in IOP, thus lowering the occurrence of 
complications often seen after trabeculectomy. In an experimental mode!, Vaudaux et al 23 
studied the aqueous dynamics through the remaining thin trabeculo-Descemet's membrane 
and found that the outflow resistance was significantly lower low but still sufficient to control 
a progressive filtration and thus to avoid the trabeculectomy-related postoperative 
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complications. This surgery requires a good surgical skill and the long-term results might 
differ depending on the surgeon's talent. The main difficulty lies in performing the dissection 
of the deep sclera and avoiding perforation of the thin trabeculo-Descemet' s membrane. In 
this series, perforation of the membrane occurred in 3 patients that were not included in the 
study. In cases of perforation into the anterior chamber, DSCI was converted into 
trabeculectomy. Sanchez et al. 24 reported that in this particular condition the success rate and 
complications were similar to that of trabeculectomy. 
Short, medium-term successes of DSCI have been reported to be favorable. Based on 
the same patient database, Karlen et al 12 reported a 55.4 % IOP reduction 3 months after 
DSCI and 53.2 % at 3 years, the mean number ofmedications per patient being reduced by 90 
%. Demailly et al 11 reported a complete success rate of 89 % at 6 months and 97 % with or 
without glaucoma medication. Shaarawy et al 13 demonstrated that DSCI was reaching, 5 
years after surgery, a 61. 9 % complete success. Mermoud et al 28 have compared the results 
after DCSI with a match group after trabeculectomy. At 24 months, they concluded that the 
success rate ofDSCI may be comparable to that of trabeculectomy, with fewer complications. 
Similar conclusions were presented by El Sayyad et al 29 while Chiselita 30 was reporting that 
trabeculectomy lowers the IOP more than the NPDS technique. However, the complication 
rate seems to be lower in NPDS. In a comparative study with DSCI on one eye and 
trabeculectomy in the other eye Ambresin et al 10 reported similar success rates with both 
procedures. Complications rates were significantly lower with DSCI than with 
trabeculectomy. However, additional procedures such as 5-FU injection or goniopuncture 
were more frequently performed in the DSCI group. To compare the effect of such additional 
procedure, Cillino et al 31 have compared the long-term effects of low-dosage mitomycin C 
(MMC) in both deep sclerectomy and trabeculectomy. At the 48 months end-point either 
procedure controlled IOP efficaciously, a low-dosage MMC can be considered a mild 
enhancement of deep sclerectomy IOP-lowering effect. 
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This paper presents the first study with a 10 year follow-up after DSCI. Our results 
indicate that DSCI remains a long-term successful procedure in stabilizing the IOP with low 
postoperative complication rates and a rather stable visual acuity. These outcomes confirm, on 
a long-term perspective, the results from previous papers in respects to efficacy and rate of 
complications compared to trabeculectomy. 10-13 • 28-31 In this context the reduced complication 
rates would present some benefice in preventing further sight degradation in eyes with 
significant glaucoma damages, and in reducing the duration, costs and extension of the 
postoperative managements. The DSCI shall be considered, in that respect, as a safer 
technique compared to trabeculectomy, and we shall advocate this surgery when a filtering 
procedure is indicated in eyes at high risks for sight threatening complications. 
In addition the visual field also remained stable for the majority (63%) of patients. 
When comparing the results at 96 months in Shaarawy study 25, reporting a 57% complete 
success rate, with our 4 7% success at 10 years, we have to take into account some elements. 
Seven patients had a failure at a mean of 109 months after surgery. Seven other patients <lied 
and 2 other were lost of follow up before the 10 years outcome. In a study on 436 patients 
with a mean age of7 l. l years, Sharma found that 29 .8% of the patients with glaucoma <lied 
within 10 years of diagnosis. 32 This figure compares with the 27.6% of mortality reported in 
this study. One of the problems mentioned by Sharma about published studies on the long-
tenn outcome of chronic glaucoma is that they are undertaken on patients who are recruited 
from the practices of glaucoma subspecialists whose patient profile tends to be skewed in the 
direction of difficult cases and include those with advance disease. The Kaplan-Meier curve 
that is generally used to demonstrate progression over time should therefore be interpreted in 
such cases with caution.32 Altogether these long term events might explain the decrease in 
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success when analyzing the surgical results on patients from the same database for 5, 8 and 10 
years follow up. 
In conclusion, DSCI off ers satisfactory results after 10 years of follow-up in 
controlling IOP in patients with primaiy and secondary open-angle glaucoma. The success 
rates were comparable with other filtration techniques while the immediate postoperative 
complication rates were low, and visual acuity remaining fairly stable. However, careful 
postoperative examinations are required to early recognize and treat bleb fibrosis or 
encapsulation with 5-FU injection or needling, as well as to identify and treat an increased 
outflow resistance through the trabeculo-Descemet's membrane by performing a 
goniopuncture. Our results indicate that DS is a viable option for the surgical therapy of open-
angle glaucoma. 
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Legends for figures 
Figure 1. 
A) One third thickness (300 µm) !imbus based superficial scleral flap measuring 5 x 5 mm is 
dissected and extended 1 mm further into clear cornea. A rectangle or square of deep sclera is 
dissected leaving a thin layer of deep sclera covering the choroid on the posterior plane. 
Schlemm's canal is exposed. 
B) Descemet's membrane exposure is performed with a mby knife. 
C) The deep sclera is carefully extended further into the comeal stroma to expose at least 1-2 
mm ofDescemet's membrane. 
D) The deep sclera is excised using a diamond blade. 
E) A toothed forceps is peeling off the inner wall of the Schlemm's canal. 
F) The collagen implant is placed radially (in the center of the deep sclerectomy dissection) 
and secured with a single 10.0 nylon suture to the thin remaining scleral layer. 
Figure 2. Mean postoperative intraocular pressure (IOP) evolution. (p<0.005). Preop indicates 
preoperative, and n the number of patients; M, month; Y, year. Bar: SD. 
Figure 3. Mean number of antiglaucoma medications per patient before and after surge1y. 
(p<0.05). Preop indicates preoperative, and n the number of patients. Bar: SD. 
Figure 4. Cumulative complete and qualified long-term success rate using Kaplan-Meier 
survival curve; n indicates the number at risk. 
Figure 5. Mean postoperative Snellen best corrected visual acuity (BCV A) evolution. 
(p=0.23). Preop indicates preoperative, and n the number of patients; M, month; Y, year. Bar: 
SD. 
Table 1. Preoperative glaucoma diagnosis 
Type of Glaucomas Number of Percentage 
patients (%) 
Primary open angle glaucoma 53 50.5 
Pseudoexfoliative glaucoma 22 20.9 
Pseudophakic glaucoma 14 13.3 
Normal tension glaucoma 5 4.8 
Pigmentary glaucoma 4 3.8 
Aphakic glaucoma 2 1.9 
Other glaucoma * 5 4.8 
*Other glaucoma includes 1 inflammatory glaucoma (Posner-Schlossman Syndrome), 2 
traumatic glaucomas, 1 corticosteroïd induced glaucoma and 1 iridocorneal dysgenesia. 
Table 2. Definitions ofpostoperative complications and additional procedures 
Complications Definition 
Hyphaema Erythrocytes in the anterior chamber 
Hypotony Postoperative IOP < 4 mmHg for > 2 weeks 
Shallow anterior chamber lridocorneal touch in the periphety 
Flat anterior chamber Lens-cornea touch 
Anterior chamber inflammation Flare or/and cells seen in the anterior chamber 
Choroidal detachment Seen in the peripheral retina using an indirect 
ophthalmoscope 
Surgery-induced cataract Rapid decrease (1 month) in the visual acuity; 
mainly cortical opacities 
Progressive cataract Slow progressive decrease in visual acuity of> 2 
lines (Snellen chart), essentially due to nuclear 
sclerosis 
Additional procedures Indication 
Subconjunctiva injections of 5 mg When filtering blebs were encysted or showed 
of 5-fluorouracil (administered in signs of fibrosis 
the lower quadrant opposite to the 
deep sclerectomy) 
Needling When filtering blebs were encysted or showed 
signs of fibrosis 
Nd: YAG laser Goniopuncture When filtration through the trabeculo-Descemet's 
membrane was clinically suspected to be 
insufficient reflected by an increasing IOP > 18 
mm Hg 
Table 3. Postoperative complications after DSCI 
Postoperative complications Number of Percentage (%) 
patients 
Flat anterior chamber 0 0 
Hyphaema 9 8.6 
Dell en 6 5.7 
Transient hypotony 2 1.9 
Bleb leakage 9 8.6 
Subtle choroidal detachment 8 7.6 
Malignant Glaucoma 1 0.9 
Surgery related cataract 0 0 
Encysted bleb 24 22.8 
Bleb fibrosis 12 11.4 
Encysted bleb + bleb fibrosis 3 2.8 
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